DURHAM – Fast-growing Velocity Clinical is building up for more speed by adding senior executives to help lead the company’s planned expansion to Europe.
Velocity was recently acquired by European-based private equity firm Global Healthcare Opportunities (GHO). house.
The new execs include:
- Dominic Clavell, Executive Vice President, Europe
- Erin Williams, Vice President, Contracts and Regulatory
- Charles-Hubert Devaux, Senior Director, Patient Recruitment
“When US companies try to expand into Europe, they tend to do this remotely, attempting to manage operations from the States. We’re breaking the mould by putting boots on the ground,” said CEO G. Paul Evans.
“Velocity is carving out a new category of pharma services. The clinical trials site landscape will look very different in the next 12 months and Velocity is well placed to take advantage of this consolidation in the market.”
Calvell, who will lead operations in Europe, has worked for Novartis, Parexel and Iqvia during his career.
“The experience of COVID has markedly changed attitudes in Europe towards commercial clinical research, which is why this expansion in Europe is so timely. We recognise that Europe poses a different set of challenges to the United States because of public healthcare structures, hence why a physical presence on the continent is paramount,” Clavell said in the announcement.
Velocity already operates 18 sites in 12 states across the U.S.
